Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angina Pectoris
Broader vasopeptidase inhibition is required to alleviate chronic angina
July 25th, 2005
Broader vasopeptidase inhibition beyond angiotensin-converting enzyme inhibition is required to alleviate chronic angina; omapatrilat shows promise in doing so. According to recent research from the United States, "Angiotensin-converting enzyme inhibition is not an effective antianginal therapy. Experimental data suggest that broader vasopeptidase inhibition may decrease the magnitude of demand-induced myocardial ischemia." B.R. Chaitman and colleagues, St. Louis University, reported, "A randomized, double-blind, placebo controlled parallel study evaluated omapatrilat, an inhibitor of angiotensin-converting enzyme and neutral endopeptidase. The...
Source: Health & Medicine Week (2005-07-25)
|
